| Aim To investigate the therapeutic efficacy of tumor derived heat shock protein 70 to tumor - bearing mice ; To Compare the therapeutic efficacy of heat shock protein 70 and worldly accepted interleukin - 2, evaluate the anti - tumor capacity of HSP70; to investigate the thera-peutic efficacy of treating malignant tumor with co - utilization of tumor - derived HSP70 and IL - 2 on tumor - bearing mice , and pro-vide significant information for HSP70 administration to treat human cancers.MethodsHSP70 was purified from the murine tumor cell line by liquid chromatography. and then identified by SDS - PAGE and western blot; the purity of purified product was analyzed by capillary electro-phoresis. The antitumor efficacies of mono - administratoion of HSP70 or IL - 2 and their combination were observed by zoopery.Result5 g HSP70 administration displayed relative anti - tumor effect, significance was observed(p <0. 05) contrasted with that of the con-trol group on tumor diameter , the survival period of this group was 28.7 ?. 5 days, significance was observed (p < 0. 05) contrasted with that of the control group(18.5 ?3.9 days). But none of the mice in this group obtained long period survival. In 10 g HSP70 administra-tion group, the survival period of the mice was over59.2 ?9.6 days, 40% of the mice survived over 90 days, and the implanted tumors dis-appeared in the end in the long survived mice, both the survival peri-od and survival rate showed obvious significance contrasted with thoseof other groups( p < 0.01). Combination of HSP70 and IL - 2 is more effective than either of the two therapeutic agents to cure tumor - bear-ing mice. Using IL -2 alone the average life of mice was only (36.63.0) days, while in mice treated with HSP70 of 10 g all tumors disappeared eventually and their survival time reached to more than 90 days. HSP70 plus IL - 2 could make tumors in 60% of mice disap-peared completely, average life time was (70.8 ?6.5) days. Both IL- 2 and HSP70 showed therapeutic efficacy to tumor - beaming mice. The best therapeutic efficacy was observed in 100,000u IL -2 and 10 g HSP70 administrations, and part was found in 50,000u IL -2 and 5 g HSP70 administrations. The effect of 100,000u IL -2 was nearly as well as that of 5 g HSP70. the average survival period of the IL ?2 50,000 group (26.2 ?.4 )days, IL-2 100,000 group (36.6 ?3. 0) days, 5 g HSP70 group (27.4 ?.9) days, significant difference was found (P <0. 05) when contrasted with the HSP70 l0μg group and control group. Incidence of ascites is 100% in CTRL groop 40% in 5μg HSP70groopN60% in 50,000u IL -2groop20% in 100,000u IL-2groop 20% in HSP70 5μg groop after surgery 0 in the other groop On the 23rd day, significance was observed(p <0.05) contras-ted with that of the control group. Conclusion Tumor derived HSP70 acted as a potential and - tumor reagent, The Combination of HSP70 and IL - 2 had apparently therapeutic effect on tumor - bearing mice. The results above will be of greater value to the study on immunothera-py of human malignant tumors. HSP70 is of specificity and obviously exceeded IL - 2 in therapeutic efficacy, This result will be valuable to the study of HSP70 in treating human malignant tumor. |
PDF Full Text Request